CPT code 87185 denotes a laboratory technical procedure to evaluate a cultured organism’s susceptibility to antimicrobial agents by detecting enzyme production (for example, beta-lactamase) that can render certain antibiotics ineffective. This molecular/biochemical susceptibility test is central to guiding targeted antimicrobial therapy, supporting antimicrobial stewardship, and informing infection control practices across inpatient and outpatient settings. Nationally, accurate reporting of such diagnostic codes affects laboratory billing, public health surveillance, and clinical decision support.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on clinical purpose and typical sites of service, an outline of what this code represents for laboratory workflows, and direction on where to find additional billing and policy guidance. The publication addresses benchmark considerations and policy updates relevant to laboratory reimbursement and documentation practices, and clarifies the clinical role of enzyme-detection susceptibility testing in informing antibiotic selection.

The report is intended for laboratory managers, billing professionals, hospital administrators, and clinicians who need a concise reference to the clinical meaning and billing context of CPT code 87185 for national practice settings. Data not available in the input are noted where applicable.